| Autor: |
Omagari, Katsuhisa, Ikuno, Nobuhiro, Imanishi, Takeo, Hayashida, Kenji, Inoue, Ken-ichiro, Senju, Masahiro, Mori, Norihiko, Tanaka, Toshiro, Nakamuta, Koji, Oda, Hidetoshi, Minamino, Atsushi, Komatsu, Kohei, Nomura, Yasuko, Kohno, Shigeru |
| Zdroj: |
Journal of Infection and Chemotherapy (Springer); December 1998, Vol. 4 Issue: 4 p209-213, 5p |
| Abstrakt: |
Abstract: The aim of interferon treatment for chronic hepatitis C is eradication of the hepatitis C virus during the early stages of the disease to prevent progression to liver cirrhosis or hepatocellular carcinoma. However, the effects of interferon on preventing the development of hepatocellular carcinoma for chronic hepatitis C without cirrhosis remain obscure. We wished to study these effects. In this retrospective study, we followed up 66 patients with chronic hepatitis C who were treated with interferon alfa-2a (total dose 324 to 792 MIU) for an average period of 3 years after treatment. Of these 66 patients, 3 patients developed hepatocellular carcinoma during the follow-up period (range, 0.3 to 2.8 years; yearly incidence 1.5%). All 3 patients were among 27 patients who did not respond to interferon treatment. Of these 3 patients, 1 patient developed liver cirrhosis after interferon treatment, and the histologic staging of the remaining 2 patients before interferon treatment was F3, according to the new Inuyama classification. None of the 18 patients who were complete responders to interferon treatment or the 21 patients with incomplete responses developed hepatocellular carcinoma. Our results suggest that patients with chronic hepatitis C who have no response to interferon treatment and histologically advanced disease should be closely followed up after interferon treatment, although the mechanism of malignant transformation to hepatocellular carcinoma in patients with chronic hepatitis C virus infection is still obscure. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
Full Text from ScienceDirect